Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Mar;46(3):884-6.
doi: 10.1128/AAC.46.3.884-886.2002.

International interlaboratory quality control program for measurement of antiretroviral drugs in plasma

Rob E Aarnoutse  1 , Corrien P W G M Verweij-van Wissen, Eleonora W J van Ewijk-Beneken Kolmer, Eveline W Wuis, Peter P Koopmans, Yechiel A Hekster, David M Burger
Affiliations

International interlaboratory quality control program for measurement of antiretroviral drugs in plasma

Rob E Aarnoutse et al. Antimicrob Agents Chemother. 2002 Mar.

Abstract

An international interlaboratory quality control program for measurement of antiretroviral drugs was initiated. The first round was confined to protease inhibitors and showed large variability in the performance of participating laboratories. The results demonstrate the need for and utility of an ongoing quality control program in this area of bioanalysis.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Performance of individual laboratories. Diagram shows the results for all measurements (all four PIs and three concentration [conc.] levels combined), arranged by laboratory. Results for individual measurements are depicted by points (note that some points are superimposed). Accuracy (y axis) is expressed as percentage relative to the true concentration (100%). The dotted lines represent the thresholds for measurements with acceptable accuracy (80 to 120%). Proportions of measurements with acceptable accuracy are placed on the x axis, above the number of each laboratory.
See this image and copyright information in PMC

References

    1. Aarnoutse, R. E., C. P. W. G. M. Verweij-van Wissen, W. J. M. Underberg, J. Kleinnijenhuis, Y. A. Hekster, and D. M. Burger. 2001. High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. J. Chromatogr. B 764:363-384. - PubMed
    1. Acosta, E. P., T. N. Kakuda, R. C. Brundage, P. L. Anderson, and C. V. Fletcher. 2000. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis. 30:S151-S159. - PubMed
    1. Back, D. J., S. H. Khoo, S. E. Gibbons, M. G. Barry, and C. Merry. 2000. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther. Drug. Monit. 22:122-126. - PubMed
    1. Barry, M. G., F. Mulcahy, C. Merry, S. Gibbons, and D. J. Back. 1999. Pharmacokinetics and potential interactions amongst anti-retroviral agents used to treat patients with HIV infection. Clin. Pharmacokinet. 36:289-304. - PubMed
    1. Hugen, P. W. H., C. P. W. G. M. Verweij-van Wissen, D. M. Burger, E. W. Wuis, P. P. Koopmans, and Y. A. Hekster. 1999. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J. Chromatogr. B 727:139-149. - PubMed